Table 1.
Results of recent trials of triplet combination therapies.
| Authors | Treatment Regimen | Phase of a Trial | Number of Participants | Median Age | Outcomes | Survivability |
|---|---|---|---|---|---|---|
| Abhishek Maiti et al. [125] |
DEC + VEN + FLT3i | II | ND AML—12 | 70 | CRc—92% | 2-year OS—80% |
| R/R AML—13 | 50 | CRc—62% | mOS—6.8 months | |||
| Musa Yilmaz et al. [126] | LIC + VEN + FLT3i | retrospective | ND AML—27 | 69 | CR/CRi—93% | mOS—NR with a median 12-month follow-up |
| Musa Yilmaz et al. [127] | DEC + VEN + QUIZ | I/II | ND AML—5 | 69 | CR/CRi—100% | mOS—14.5 months |
| R/R AML—23 | - | CR/CRi—78% | mOS—7.6 months | |||
| Nicholas J. Short et al. [128] | AZA + VEN + GILT | I/II | ND AML—21 | 68 | ORR—100% | 6-month OS—95%, estimated 1-year OS—80% |
| R/R AML—19 | 68 | ORR—74% | mOS—5.8 months, 1-year OS—27% | |||
| Chong Chyn Chua et al. [129] | LDAC + VEN + MIDO | Ib/II | ND AML—18 | 77 | ORR—77.8% | mOS—NR, with a median 18-months follow-up |
| Juan Miguel Bergua-Bergues et al. [130] | AZA + VEN + QUIZ or LDAC + VEN + QUIZ | I/II | ND AML—45 | 76.5 | ORR—54% | unknown |
| Nicholas Short et al. [131] | AZA + VEN + GILT | II | ND AML—30 | 71 | CR/CRi—96% | Estimated 1-year OS—86% |
| Tareq Abuasab et al. [132] | CLIA + VEN + GILT | II | ND AML—8 | 55 | CR—88% | mOS—22.4 months |
Abbreviations: DEC—Decitabine; VEN—Venetoclax; FLT3i—FLT3 inhibitor; LIC—Lower Intensity Chemotherapy; QUIZ—Quizartinib; AZA—Azacitidine; GILT—Gilteritinib; CLIA—Cladribine, Idarubicin, Cytarabine; LDAC—Low-Dose Cytarabine; MIDO—Midostaurin; ND—Newly Diagnosed; R/R—Relapsed/Refractory; CRc—Composite Complete Remission; CR/CRi—Complete Remission/Complete Remission with Incomplete Hematologic Recovery; ORR—Overall Response Rate; NR—Not Reached.